Sonnet BioTherapeutics Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SONN research report →
Price Chart
About the company
Sonnet BioTherapeutics Holdings, Inc. , a biotechnology company based in Princeton, New Jersey, operates in the clinical stage with a primary focus on oncology. The firm is dedicated to developing novel platforms for creating biologic medicines that can exhibit either singular or dual therapeutic mechanisms.
- CEO
- Raghu Rao
- IPO
- 2006
- Employees
- 13
- HQ
- Princeton, NJ, US
Get TickerSpark's AI analysis on SONN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.43M
- P/E
- -0.53
- PEG
- -0.01
- P/S
- 0.00
- P/B
- 0.48
- EV/EBITDA
- 1.15
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -462.39%
- ROIC
- -116.41%
Latest fiscal year · YoY change
- Revenue
- $1.00M+5268.8%
- Gross Profit
- $0-100.0%
- Op Income
- $-15,844,115
- Net Income
- $-16,112,737-116.6%
- EPS
- $-3.95+65.2%
- OCF Growth
- -49.0%
- FCF Growth
- -49.0%
- 52W High
- $19.30
- 52W Low
- $1.08
- 50D MA
- $4.58
- 200D MA
- $3.04
- Beta
- 1.47
- RSI (14)
- 28
- Avg Volume
- 1.11M
No earnings-call transcripts are available for SONN yet.
- Free Float
- 100.7%
- Shares Outstanding
- 6.69M
- Float Shares
- 6.74M
of shares held by institutions
9 13F filers
Buy/sell ratio 0.13. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Carroll Financial Associates, Inc. | 10 | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 2, 25 | Kenney Richard T | other | 163,760 |
| Dec 2, 25 | Kenney Richard T | other | 86,505 |
| Dec 2, 25 | Kenney Richard T | other | 16,891 |
| Dec 2, 25 | Kenney Richard T | other | 86,505 |
| Dec 2, 25 | Kenney Richard T | other | 200 |
| Dec 2, 25 | Kenney Richard T | sell | 69,614 |
| Dec 2, 25 | Kenney Richard T | sell | 9,374 |
| Dec 2, 25 | Kenney Richard T | sell | 320,000 |
| Dec 2, 25 | Kenney Richard T | sell | 163,760 |
| Dec 2, 25 | MCANDREW STEPHEN J | sell | 6,446 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SONN coverage
Recent articles, reports, and earnings notes.
No research on SONN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SONN report →Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
globenewswire.com · Dec 2
Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc
globenewswire.com · Dec 2
Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting
globenewswire.com · Nov 18
Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma
globenewswire.com · Oct 15
Sonnet to Present at the MedInvest Biotech & Pharma Conference
globenewswire.com · Sep 19
Sonnet Releases Virtual Investor "What This Means" Segment
globenewswire.com · Aug 11
Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer
globenewswire.com · Aug 4
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Sonnet BioTherapeutics, Inc. (NASDAQ: SONN)
globenewswire.com · Jul 14
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.